Register Login

PYXIS ONCOLOGY, INC. (PYXS)

SymbolPYXS
NamePYXIS ONCOLOGY, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, Massachusetts, 02140, United States
Telephone+1 617 221-9059
Fax—
Email—
Websitehttps://www.pyxisoncology.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001782223
Description

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Additional info from NASDAQ:
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

2026-07-02 20:30

Dupont Jakob 🟡 adjusted position in 35.0K shares (1 derivative) of Pyxis Oncology, Inc. (PYXS) at $3.06 Transaction Date: Jun 30, 2026 | Filing ID: 294708

Read more
2026-07-02 20:20

(75% Positive) PYXIS ONCOLOGY, INC. (PYXS) Announces Enrollment Update for exercised Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment

Read more
2026-07-02 17:10

New Form SCHEDULE 13G/A - Pyxis Oncology, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0000919574-26-004255 <b>Size:</b> 19 KB

Read more
2026-06-30 11:30

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Read more
2026-06-15 20:22

(99% Neutral) PYXIS ONCOLOGY, INC. (PYXS) Files Form 8-K

Read more
2026-05-14 11:36

(30% Negative) PYXIS ONCOLOGY, INC. (PYXS) Reports Q2 2026 Financial Results

Read more
2026-05-13 11:30

Pyxis Oncology to Participate in Upcoming Investor Conferences

Read more
2026-05-07 20:05

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Read more
2026-04-30 08:40

New Form DEFA14A - Pyxis Oncology, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-194051 <b>Size:</b> 2 MB

Read more
2026-04-30 08:36

New Form DEF 14A - Pyxis Oncology, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-194032 <b>Size:</b> 1 MB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06795412 Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid … Phase1 Advanced Solid Tumors Recruiting 2025-04-15 2027-12-06 ClinicalTrials.gov
NCT05718557 Study of PYX-106 in Solid Tumors Phase1 Solid Tumor Active_Not_Recruiting 2023-05-23 2026-05-01 ClinicalTrials.gov
NCT05720117 A Study of PYX-201 in Advanced Solid Tumors Phase1 Solid Tumor Recruiting 2023-03-14 2028-06-30 ClinicalTrials.gov
NCT03389802 Phase I Study of APX005M in Pediatric Central Nervous System Tumors Phase1 Glioblastoma Multiforme Active_Not_Recruiting 2018-03-01 2026-06-30 ClinicalTrials.gov
NCT02706353 APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic … Phase1 Melanoma Terminated 2017-06-02 2025-03-10 ClinicalTrials.gov
Total clinical trials: 5
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
PYX-201 Other Phase PHASE1 Solid Tumor RECRUITING NCT05720117
APX005M treatment for newly diagnosed DIPG patients Drug Phase PHASE1 Glioblastoma Multiforme ACTIVE_NOT_RECRUITING NCT03389802
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients Drug Phase PHASE1 Glioblastoma Multiforme ACTIVE_NOT_RECRUITING NCT03389802
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
pembrolizumab Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumors RECRUITING NCT06795412
PYX-106 Other Phase PHASE1 Solid Tumor ACTIVE_NOT_RECRUITING NCT05718557
Pembrolizumab Other Phase PHASE1 Melanoma TERMINATED NCT02706353
APX005M Other Phase PHASE1 Melanoma TERMINATED NCT02706353
APX005M treatment for newly diagnosed DIPG patients Drug Phase PHASE1 Glioblastoma Multiforme ACTIVE_NOT_RECRUITING NCT03389802
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients Drug Phase PHASE1 Glioblastoma Multiforme ACTIVE_NOT_RECRUITING NCT03389802
pembrolizumab Other Phase PHASE1 Advanced Solid Tumours RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Advanced Solid Tumours RECRUITING NCT06795412
PYX-201 Other Phase PHASE1 Solid Tumor RECRUITING NCT05720117
pembrolizumab DRUG Phase PHASE1 Advanced Solid Tumours RECRUITING NCT06795412
PYX-201 DRUG Phase PHASE1 Advanced Solid Tumours RECRUITING NCT06795412
PYX-106 DRUG Phase PHASE1 Solid Tumor ACTIVE_NOT_RECRUITING NCT05718557
APX005M treatment for newly diagnosed DIPG patients BIOLOGICAL Phase PHASE1 Glioblastoma Multiforme ACTIVE_NOT_RECRUITING NCT03389802
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients BIOLOGICAL Phase PHASE1 Glioblastoma Multiforme ACTIVE_NOT_RECRUITING NCT03389802
Total products: 34